# Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy

> **NCT03776643** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 24 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis to Birch Pollen
- With a Positive Skin Prick Test to Birch Pollen

## Interventions

- **DRUG:** ILT-101 ld-(IL2)

## Key facts

- **NCT ID:** NCT03776643
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2022-08-16
- **Final completion:** 2022-08-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776643, "Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03776643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*